For the third quarter of 2026, analysts expect Liquidia Technologies to report consensus revenue of $214.15 million and earnings of $0.77 per share, while the current stock price of $44.40 trades below the average analyst target of $54.38.
Investors are primarily focused on the commercial sales momentum and market share capture of YUTREPIA (inhaled treprostinil) following its full market launch.
Preliminary sales of $222.7 million shared in October suggest the company will comfortably beat the $201.5 million analyst consensus for the drug. Beyond sales, the market is watching for details regarding the $380.7 million settlement with United Therapeutics and clinical updates on the L606 pipeline candidate as Liquidia targets a $1 billion revenue run rate by 2027.